FDA Fast-Tracks First Vaping Cessation Treatment for Cytisinicline
Achieve Life Sciences receives FDA's National Priority Voucher for cytisinicline, potentially the first approved treatment to help people quit vaping and e-cigarettes.
Achieve Life Sciences receives FDA's National Priority Voucher for cytisinicline, potentially the first approved treatment to help people quit vaping and e-cigarettes.
FDA accepted cytisinicline NDA for smoking cessation, with a PDUFA date of June 20, 2026. This marks a significant step, potentially offering the first new FDA-approved therapy in two decades to combat nicotine dependence, supported by strong clinical data and safety.